ATE363908T1 - Verwendung von 7-alpha-substituierten steroiden zur behandlung von neuropsychiatrischen erkrankungen - Google Patents

Verwendung von 7-alpha-substituierten steroiden zur behandlung von neuropsychiatrischen erkrankungen

Info

Publication number: ATE363908T1
Authority: AT; Austria
Prior art keywords: alpha; steroids; hydroxy; neuropsychiatric diseases; substituted steroids
Prior art date: 1996-04-09

Application number

AT97915603T

Other languages

English (en)

Inventor

Richard Lathe

Kenneth Rose

Jonathan Seckl

Ruth Best

Joyce Lai Wah Yau

Caroline Mckenzie Leckie

Original Assignee

Univ Edinburgh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-09

Filing date

1997-04-04

Publication date

2007-06-15

1996-04-09 Priority claimed from GBGB9607289.7A external-priority patent/GB9607289D0/en

1996-04-24 Priority claimed from GBGB9608445.4A external-priority patent/GB9608445D0/en

1997-03-10 Priority claimed from GBGB9704905.0A external-priority patent/GB9704905D0/en

1997-04-04 Application filed by Univ Edinburgh filed Critical Univ Edinburgh

2007-06-15 Application granted granted Critical

2007-06-15 Publication of ATE363908T1 publication Critical patent/ATE363908T1/de

Links

150000003431 steroids Chemical class 0.000 title abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
201000010099 disease Diseases 0.000 title 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical class OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical class C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 abstract 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
208000017701 Endocrine disease Diseases 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Chemical class C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 abstract 1
ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Chemical class O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 abstract 1
229940061641 androsterone Drugs 0.000 abstract 1
238000003149 assay kit Methods 0.000 abstract 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
229940107161 cholesterol Drugs 0.000 abstract 1
150000001841 cholesterols Chemical class 0.000 abstract 1
230000037410 cognitive enhancement Effects 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
229930182833 estradiol Chemical class 0.000 abstract 1
229960005309 estradiol Drugs 0.000 abstract 1
125000001033 ether group Chemical group 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229960000249 pregnenolone Drugs 0.000 abstract 1
ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical class C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 abstract 1
238000010998 test method Methods 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0077—Ethers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
- C12P33/06—Hydroxylating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Psychiatry (AREA)
Obesity (AREA)
Hematology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Steroid Compounds (AREA)

AT97915603T 1996-04-09 1997-04-04 Verwendung von 7-alpha-substituierten steroiden zur behandlung von neuropsychiatrischen erkrankungen ATE363908T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9607289.7A GB9607289D0 (en)	1996-04-09	1996-04-09	Process of producing a 7a-hydroxy-sustituted steroids novel steroids so produced and novel uses thereof
GBGB9608445.4A GB9608445D0 (en)	1996-04-24	1996-04-24	Process of producing a 7A-hydroxy-substituted steroids,novel steroids so produces and novel uses thereof
GBGB9704905.0A GB9704905D0 (en)	1997-03-10	1997-03-10	Neurosteroids

Publications (1)

Publication Number	Publication Date
ATE363908T1 true ATE363908T1 (de)	2007-06-15

Family

ID=27268229

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97915603T ATE363908T1 (de)	1996-04-09	1997-04-04	Verwendung von 7-alpha-substituierten steroiden zur behandlung von neuropsychiatrischen erkrankungen

Country Status (9)

Country	Link
US (1)	US6420353B1 (de)
EP (1)	EP0954317B1 (de)
JP (1)	JP2000511404A (de)
AT (1)	ATE363908T1 (de)
AU (1)	AU716503B2 (de)
CA (1)	CA2250874A1 (de)
DE (1)	DE69737791D1 (de)
NZ (1)	NZ331975A (de)
WO (1)	WO1997037664A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6627738B2 (en)	1995-09-15	2003-09-30	Duke University	No-modified hemoglobins and uses therefor
US6686486B1 (en)	1997-05-07	2004-02-03	Padma Marwah	Process for effecting allylic oxidation
US5869709A (en) *	1997-05-07	1999-02-09	Humanetics Corporation	Process for effecting allylic oxidation
US6252119B1 (en)	1997-07-28	2001-06-26	Salvador Jorge Antonio Riberiro	Copper-catalysed allylic oxidation using alkyl hydroperoxide
EP1726307A3 (de) *	1997-10-06	2007-04-04	The Board Of Trustees Of The Leland Stanford Junior University	Methode zur Behandlung von durch Glycocorticoidstörungen verursachten Psychosen
AU747956B2 (en) *	1997-10-06	2002-05-30	Board Of Trustees Of The Leland Stanford Junior University	Methods for treating psychosis associated with glucocorticoid related dysfunction
US6794374B1 (en)	1997-11-19	2004-09-21	Humanetics Corporation	Use of Δ5-androstene-3β-OL7,17-dione in the treatment of arthritis
US6384251B1 (en)	1998-03-18	2002-05-07	Humanetics Corporation	Process for effecting allylic oxidation using dicarboxylic acid imides and chromium reagents
CA2328411C (en)	1998-05-15	2008-12-16	Alan F. Schatzberg	Glucocorticoid receptor antagonists for the treatment of dementia
JP4676061B2 (ja) *	1998-07-30	2011-04-27	アボット・ラボラトリーズ	グルココルチコイド選択性薬剤
US6153606A (en)	1998-10-16	2000-11-28	Humanetics Corporation	Memory enhancement by the administration of Δ5-androstene-3β-ol-7,17-dione and 3β esters thereof
FR2799206A1 (fr) *	1999-10-05	2001-04-06	Transgene Sa	Procede de production de steroides modifies par fermentation de levures
US6620802B1 (en)	1999-11-23	2003-09-16	Corcept Therapeutics, Inc.	Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
GB0003524D0 (en) *	2000-02-15	2000-04-05	Btg Int Ltd	Cytoprotective steroids (II)
GB2363984A (en) *	2000-06-29	2002-01-16	Hunter Fleming Ltd	Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2363983A (en) *	2000-06-29	2002-01-16	Hunter Fleming Ltd	Protection against neuronal damage using 7-hydroxyepiandrosterone
US20030013692A1 (en) *	2001-01-19	2003-01-16	Gullans Steven R.	Methods of treating neurological disorders
CA2954889A1 (en)	2001-03-09	2002-09-19	University Of Kentucky Research Foundation	Cytochrome p450s and uses thereof
JP2006503819A (ja) *	2002-08-29	2006-02-02	ザリージェンツオブザユニバーシティオブカリフォルニア	骨形成を増進するための作用剤および方法
US9532994B2 (en)	2003-08-29	2017-01-03	The Regents Of The University Of California	Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
GB0403889D0 (en) *	2004-02-21	2004-03-24	Univ Edinburgh	Uses of er-beta modulators
US7304171B2 (en) *	2004-05-27	2007-12-04	Migenix Corp.	Compounds and methods for cytoprotection
US7910755B2 (en)	2004-09-29	2011-03-22	Harbor Biosciences, Inc.	Stem cell expansion and uses
US20060234993A1 (en) *	2005-04-13	2006-10-19	Eric Marchewitz	Use of androstane derivatives for enhancing physical performance
AU2007217366A1 (en)	2006-02-27	2007-08-30	The Regents Of The University Of California	Oxysterol compounds and the hedgehog pathway
TW200820977A (en) *	2006-08-08	2008-05-16	Organon Nv	Use of glucocorticoid receptor antagonists for treatment of infectious conditions
US9526737B2 (en)	2007-12-03	2016-12-27	The Regents Of The University Of California	Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
CA2872751A1 (en)	2012-05-07	2013-11-14	The Regents Of The University Of California	Oxysterol analogue oxy133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
JP2016517888A (ja)	2013-05-02	2016-06-20	ザリージェンツオブザユニバーシティオブカリフォルニア	骨選択的骨形成のオキシステロール骨標的薬剤
US10828312B2 (en)	2018-10-29	2020-11-10	Jun Tan	Lithium cholesterol compositions, including, but not limited to lithium cholesterol sulfate compositions, and methods of treatment for Alzheimer's disease and neurological disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2418603A (en)	1941-02-05	1947-04-08	Schering Corp	Method of preparing estradiol from equilin and intermediates obtained thereby
US3409643A (en)	1966-03-11	1968-11-05	Schering Corp	Process for the preparation of 17alpha-alkynl-17beta-alkanoyloxy steroids of the androstane and estrane series
FR2235949B1 (de)	1973-06-18	1978-03-17	Roussel Uclaf
DE2449327C2 (de)	1974-10-14	1983-12-22	Schering AG, 1000 Berlin und 4709 Bergkamen	7 α-Hydroxy-östradiole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
YU243975A (en)	1974-10-14	1982-06-30	Schering Ag	Process for obtaining 7-hydroxyestradiols
FR2336413A1 (fr)	1975-12-22	1977-07-22	Roussel Uclaf	Nouveau procede de preparation du 3,17b-dihydroxy 7-oxo-estra 1,3,5(10)-triene
AU647528B2 (en)	1990-08-29	1994-03-24	Humanetics Corporation	Treatment process for promoting weight loss employing a substituted delta5-androstene
US5292730A (en) *	1990-08-29	1994-03-08	Humanetics Corporation	Modulation of immune system with Δ5-androstenes
FR2696934B1 (fr)	1992-10-20	1995-06-02	Conservatoire Nal Arts Metiers	Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
EP0666746B1 (de)	1993-09-02	2001-07-04	Humanetics Corporation	Delta - 5 - Androstene, die das Halten des Gewichts oder den Gewichtsverlust fördern und Behandlungsverfahren
US5420028A (en) *	1993-10-13	1995-05-30	Northeastern Ohio Universities	Truncated human cholesterol 7α-hydroxylase, method of production and use thereof
GB9421093D0 (en) *	1994-10-19	1994-12-07	Univ Edinburgh	Hippocampus-associated proteins, DNA sequences coding therefore and uses thereof
FR2733912B1 (fr)	1995-05-11	1997-07-18	Conservatoire Nat Arts	Compositions pharmaceutiques contenant des derives de steroides impliques dans le declenchement de la reponse immunitaire

1997
- 1997-04-04 WO PCT/GB1997/000955 patent/WO1997037664A2/en not_active Ceased
- 1997-04-04 AT AT97915603T patent/ATE363908T1/de not_active IP Right Cessation
- 1997-04-04 EP EP97915603A patent/EP0954317B1/de not_active Expired - Lifetime
- 1997-04-04 JP JP09535961A patent/JP2000511404A/ja not_active Ceased
- 1997-04-04 NZ NZ331975A patent/NZ331975A/xx unknown
- 1997-04-04 DE DE69737791T patent/DE69737791D1/de not_active Expired - Lifetime
- 1997-04-04 AU AU23021/97A patent/AU716503B2/en not_active Ceased
- 1997-04-04 CA CA002250874A patent/CA2250874A1/en not_active Abandoned
1998
- 1998-10-08 US US09/168,218 patent/US6420353B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU716503B2 (en)	2000-02-24
NZ331975A (en)	2000-12-22
AU2302197A (en)	1997-10-29
EP0954317A2 (de)	1999-11-10
DE69737791D1 (de)	2007-07-19
WO1997037664A3 (en)	1997-12-04
WO1997037664A2 (en)	1997-10-16
CA2250874A1 (en)	1997-10-16
EP0954317B1 (de)	2007-06-06
US6420353B1 (en)	2002-07-16
JP2000511404A (ja)	2000-09-05

Legal Events

Date	Code	Title	Description
2007-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69737791D1 (de)	2007-07-19	Verwendung von 7-alpha-substituierten steroiden zur behandlung von neuropsychiatrischen erkrankungen
NZ298567A (en)	2000-01-28	Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment
SE8603046D0 (sv)	1986-07-08	Substituted androsta-1,4-diene-3,17-diones and process for their preparation
ATE274356T1 (de)	2004-09-15	Verwendung von angiostatische steroide in photodynamischer therapie
ATE109343T1 (de)	1994-08-15	Dosierungseinheit zur transdermalen absorbierung für estradiol und sonstige estrogene steroide.
BR9710918A (pt)	2000-01-11	Método de tratamento ou redução de isquemia de miocárdio ou doença arteriocoronária ou acidentes cardiovasculares e uso de progesterona e polìmero de ácido mpolicarboxìlico de ligação cruzada.
CA2069483A1 (en)	1991-08-22	Steroid sulphatase inhibitors
ATE229539T1 (de)	2002-12-15	Verfahren zur anreichung des verhältnisses der r- epimers von 16,17-acetal derivate von 21-acyloxy pregan-1,4-dien-11.beta.,16.alpha.,17.alpha.- triol-3,20-dionen
ES533261A0 (es)	1985-02-01	Procedimiento para la preparacion de 1-alquil-androsta-1,4-dien-3,17-dionas
ATE1710T1 (de)	1982-11-15	Verfahren zur herstellung von chenodeoxycholsaeure und zwischenprodukte dazu.
Pechet	1955	Method for the chromatographic separation of very polar steroids
ATE342721T1 (de)	2006-11-15	Steroide als neurochemische stimulatoren des nasenraumes zur linderung der prämenstrualen symptome
ATE107656T1 (de)	1994-07-15	Verfahren zur herstellung von 14-alpha-hydroxy-4- androsten-3,6,17, trion.
AU571073B2 (en)	1988-03-31	Pharmaceutical composition of 9a, 11b-dichcoro-16a-methl-21-oxycarbonyl dicyclohexycmethycoxy pregna-1,4-diene-3,20-dione
DE69514724D1 (de)	2000-03-02	Verfahren zur Herstellung von 20-oxo, 17-alpha, 21-dihydroxy Steroidederivate und neue Zwischenprodukte dafür
IL56495A0 (en)	1979-03-12	Steroids of the pregnane series substituted in the 17-position and the jpreparation and use thereof
IL52436A (en)	1982-08-31	Process for the preparation of cholesta-5,7-diene-3beta,25-diol and 1alpha,3beta,25-triol and corresponding cholesta-5,22-diene-7-ones as intermediates therefor
ATE1954T1 (de)	1982-12-15	Verfahren zur herstellung von 19-hydroxysteroiden der androstan- und pregnanreihe.
AU531189B2 (en)	1983-08-11	1,4-cycloalkano-oxazepines
FI793027A7 (fi)	1981-01-01	Uusia androstaani-, estraani- ja pregnaani-sarjan 3 -amino-2 -hydroksi-steroideja, menetelmiä niiden vavalmistamiseksi sekä farmaseuttisia yhdistelmiä.
ZA79318B (en)	1980-01-30	New steroids of the pregnane series substituted in the 17-position,and their manufacture and use
GB854343A (en)	1960-11-16	Process for the preparation of 3-oxo-í¸ and 3-oxo-í¸-steroids
Ruzicka	1936	Relationship of the sex hormone groups
Jirapinyo et al.	1997	Vasomotor and Psychological Symptoms in Climacteric Women in Ramathibodi Hospital
DE59108471D1 (de)	1997-02-20	Verfahren zur herstellung von 4-pregnen-3,20-dion und seinen derivaten